

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

Please amend the first full paragraph on page 2 of the application, beginning on line 5 with "The present invention provides," as follows:

The present invention provides a novel salt of O-desmethyl-venlafaxine, O-desmethyl-venlafaxine succinate (hereinafter referred to as "ODV succinate"). The novel salt of the present invention has properties which are particularly suitable for use as a drug, including improved solubility, permeability, and bioavailability. For example, ODV succinate is well absorbed in the gastrointestinal tract. Furthermore, oral administration of ODV succinate results in a lower incidence of ~~nauseau~~ nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus than oral administration of venlafaxine, ~~O-desmethyl-venlafaxine, and salts of O-desmethyl-venlafaxine other than ODV succinate.~~ Additionally, sustained release oral formulations of ODV succinate result in a lower incidence of ~~nauseau~~ nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus than oral administration of venlafaxine, ~~O-desmethyl-venlafaxine and salts of O-desmethyl-venlafaxine (other than sustained release oral formulations of ODV succinate).~~ Pharmaceutical compositions comprising ODV succinate and pharmaceutically acceptable carriers or excipients are also provided. Preferably, the pharmaceutical compositions comprise an amount of ODV succinate effective to treat the desired indication in an animal, such as a human.

AMENDMENTS TO THE DRAWINGS:

The attached sheet of drawings includes changes to Figure 8. Figure 8 contains a typographical error and labels two thermogravimetric analyses as Form I. The Figure legend correctly states that the Figure presents Forms I, II, IV, and the amorphous form. Applicants have corrected the Figure to properly label the forms.

Attachments: Replacement Sheet for Figure 8
 Annotated Sheet showing change made